A new study in the peer-reviewed journal Psychedelic Medicine demonstrated in this sample that Muslims living in the United States (MLUS) showed moderate openness to psychedelics in mental health therapy. Click here to read the article now.
MLUS have a history of rejecting mental health services. Syed Fayzan Rab, MD, a researcher at the Emory Center for Psychedelics and Spirituality, and coauthors of the study, reported a weak negative correlation between rejection attitudes toward mental health and acceptance of psychedelics.
"Moderate openness to psychedelics was noted overall, and higher education correlated with favorable attitudes toward both mental health and psychedelics," stated Rab and team.
The findings suggest that providing education about psychedelic therapies could lower barriers to considering this treatment. "Future research could build on existing strategies, such as a short educational intervention that could be provided to a group of Muslim participants to see if it improves attitudes and perceptions around psychedelics," stated the investigators.
About the Journal
Psychedelic Medicine is the first peer-reviewed journal to publish original research papers on every aspect of psychedelic medicine, including basic science, clinical, and translational research, as well as medical applications. This journal provides a vital resource for clinicians and patients alike who are invested in the potential efficacy of psychedelic drugs currently undergoing research in preclinical and clinical studies as an alternative or supplement to traditionally manufactured pharmaceuticals to treat depression, anxiety, addiction, demoralization, and other mental health conditions. Visit the Psychedelic Medicine website to learn more.
About Mary Ann Liebert, Inc., a Sage Company
Mary Ann Liebert, Inc. is a global media company dedicated to publishing and delivering impactful peer-reviewed research in biotechnology & life sciences, specialized clinical medicine, public health and policy, and technology & engineering. Since its founding in 1980, the company has focused on providing critical insights and content that empower researchers and clinicians worldwide to drive innovation and discovery.
